England’s Cost Effectiveness Rejection Is Another Setback For Eisai And Biogen’s Leqembi
Cost watchdog NICE has blocked Leqembi’s use, but a pricing deal could unlock access to the beta-amyloid targeting drug
Cost watchdog NICE has blocked Leqembi’s use, but a pricing deal could unlock access to the beta-amyloid targeting drug